December 22, 2022
Sunlenca approved by FDA for use with other antiretrovirals for the treatment of HIV-1 infections
Gilead Sciences, Inc. has announced that Sunlenca® (lenacapavir), in combination with other antiretroviral(s) (ARV), has been granted approval by the U.S. Food and Drug Administration (FDA) for the treatment of HIV-1 infection in heavily treatment-experienced (HTE) adults with multi-drug resistant (MDR) HIV-1 infection.
Sunlenca belongs to a new class of drugs called capsid inhibitors and is designed to inhibit HIV-1 at
multiple stages of its lifecycle and may work against HIV strains that are resistant to other HIV drugs.
Sunlenca offers a new, twice-yearly treatment option for adults with HIV that is not adequately controlled by their current treatment regimen.